Patent intelligence · US
US 6894026
Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
Patent details — US 6894026
- Jurisdiction
- US
- Status
- expired
- Grant date
- May 17, 2005
- Expiration
- May 12, 2025
- Applicant
- Atossa Healthcare, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K31/395
Quick answer
US 6894026 (Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders) is held by Atossa Healthcare, Inc.. Status: expired. Granted May 17, 2005. Expires May 12, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Atossa Healthcare, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/395
More from Atossa Healthcare, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12281056
Methods for making and using endoxifen
granted -
US 12275684
Methods for making and using endoxifen
granted -
US 12201591
Sustained release compositions of endoxifen
granted -
US 12071391
Methods for making and using endoxifen
granted -
US 11680036
Methods for making and using endoxifen
granted -
US 11572334
Methods for making and using endoxifen
granted -
US 11261151
Methods for making and using endoxifen
granted
Frequently asked questions
What is US patent 6894026?
US 6894026 (Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders) is held by Atossa Healthcare, Inc.. Status: expired. Granted May 17, 2005. Expires May 12, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6894026?
Atossa Healthcare, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 6894026 expire?
Our index shows an expiration date of May 12, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.